Colonics
About Me
Recent Posts
- Statement From American Heart Association CEO Nancy Brown On Congressional Approval Of The PACT Act
- World TB Day - Canada's Leading The International Fight Against TB, But More Work Must Be Done In Canada's North
- CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS
- Access MediQuip enhances Recall Management Service for implantable devices
- Biomoda enters into agreements with syndicate of institutional investors for up to $2.0M
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 | 31 | ||||
Friends
Links
Entry 1 of 1166
Last Page | Next Page
11/17/2009
-
Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma
|
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that educator John F. Thompson, MD, don of Melanoma and Surgical Oncology at the teaching hospital of Sydney, controller of the Melanoma principle Australia, and Lead sleuth of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on november 11 21, 2009 in Berlin, Germany. More: - From the site |
Post A Comment! :: Send to a Friend! |
Share and enjoy
